24/7 Market News Snapshot 27 June, 2025 – Pliant Therapeutics, Inc. Common Stock (NASDAQ:PLRX)
DENVER, Colo., 27 June, 2025 (www.247marketnews.com) – (NASDAQ:PLRX) are discussed in this article.
Pliant Therapeutics, Inc. (PLRX) has emerged as a focal point in the pharmaceutical sector, exhibiting a substantial surge in share price today, rising approximately 10.46% to $1.436 from a previous close of $1.30. With trading volume reaching 8.18 million shares, this uptick reflects robust investor interest and optimism surrounding the company’s potential in developing innovative therapies.
In a significant development, Pliant Therapeutics announced a strategic decision to discontinue its bexotegrast program aimed at treating idiopathic pulmonary fibrosis (IPF). This move comes on the heels of a rigorous evaluation of data from the BEACON-IPF Phase 2b/3 clinical trial, conducted with input from an independent Data Safety Monitoring Board (DSMB). The analysis cited unfavorable safety outcomes associated with bexotegrast, prompting the company to prioritize patient welfare over continued development.
Despite initial indications that bexotegrast could enhance forced vital capacity in IPF patients, subsequent findings revealed an alarming risk profile, including elevated rates of respiratory complications and hospitalizations linked to disease progression. Dr. Bernard Coulie, President and CEO of Pliant Therapeutics, articulated the company’s commitment to patient safety, acknowledging the disappointment surrounding the trial’s results.
As Pliant reframes its future direction, attention shifts toward ongoing oncology programs, particularly the Phase 1 trial of PLN-101095, which is showing promise in treating solid tumors resistant to current therapies. The firm remains resolute in its mission to foster innovative treatment solutions through its proprietary drug discovery platform, focused on diverse disease areas.
Pliant Therapeutics continues to navigate the complexities of drug development while keeping patient-centric approaches at the forefront of its operations, signaling potential for future advancements in the therapeutic landscape.